Navigation Links
Aethlon Medical (AEMD) Note: Cancer Immunotherapy Article, Introduction to Dr. Douglas Taylor
Date:10/24/2013

ector T cells. Treatment of activated T cells with anti-PD-L1 antibodies reduce T cell proliferation, which correlates with attenuated IL-2 secretion.  In vitro cytotoxicity studies and in vivo growth inhibition can be restored utilizing anti-PD-L1 antibodies or by genetic silencing of PD-1. The expression of PD-L1 on tumor cells inhibits anti-tumor immunity through engagement of PD-1 on effector T cells. Expression of PD-L1 on tumors is correlated with reduced survival in many tumor types.

Due to the role of these molecules in immune regulation and correlation with cancer outcomes, these pathways are being targeted for immunotherapy. Bristol Myers' experimental PD-1 inhibitor Nivolumab and Merck's candidate, MK-3475, block the PD-1/PD-L1 interaction, allowing the immune system to react with the tumor cells. Yervoy targets a similar checkpoint, inhibiting the CTLA-4 pathway. Unlike genetically targeted drugs, which disrupt mutations that fuel tumor growth, the new agents treat the immune system. Current interest in targeting these molecular pathways raises a concern that their normal function acts as to modulate the immune system to prevent attacks on healthy cells. Studies in murine models deficient for PD-1 developed dilated cardiomyopathy and congestive heart failure and that expression of PD-1 may also prevent autoimmune diseases. Based on the critical role of PD-1 and CTLA-4, targeting their expression may be problematic resulting in serious side effects on the host. However, an essential component of the activity of such molecules may be due to their presence on exosomes released by tumor cells. We previously demonstrated the presence of these immunoregulatory molecules on tumor-derived exosomes and their ability to suppress T cell activation and proliferation (Taylor et al. Clinical Cancer Research, 9: 5113-5119, 2003). Thus, a reasonable approach that does not result in systemic toxicity would be the removal of these immunoregulatory
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Aethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.
2. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
3. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
4. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
5. Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
6. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
7. Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
8. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
9. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
10. Aethlon Medical (AEMD) Note: Since September 30th, 2011 / Thank You Shareholders
11. Aethlon Medical Discloses CEO Interview
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... 24 BioTrends Research Group, Inc. recently published its ... report is based on online ... interventional radiologists and interventional nephrologists). It provides an in-depth ... practice patterns related to both vascular access placement and ...
... Mass., Aug. 24 Echo Therapeutics, Inc. (OTC Bulletin ... needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal ... for transdermal drug delivery, today announced the completion of ... designed to evaluate the ability of Prelude to ablate ...
Cached Medicine Technology:Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market 2Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream 2Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream 3
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather Pugh earned ... care for patients at this natural health care center in Winamac. , "Oftentimes patients ... said. "Heather's role is vital to our approach because we want to focus on ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... in “a trending profession” that comprises a growing percentage of U.S. physicians, and ... , That was one part of the message delivered by John W. Becher, ...
(Date:8/1/2015)... Humble, TX (PRWEB) , ... August 01, 2015 , ... ... common concern among both men and women often causing pain and discomfort. Those who ... to this circulatory problem, and Northeast Houston Vein Center is doing what it can ...
(Date:8/1/2015)... ME (PRWEB) , ... August 01, 2015 , ... Tina ... Retail Champions.” , Wilcoxson was given that honor by the National Retail Federation, the ... retail industry. Wilcoxson was one of three Maine business owners to be named as ...
(Date:8/1/2015)... and Greenwich, CT (PRWEB) , ... August 01, ... ... a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical ... — incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... 12, 2008) - Beta-blocker drugs may help prevent heart ... of death and major stroke, says a major study ... journal, The Lancet. , POISE is the worlds largest ... the effects of a beta-blocker versus placebo given to ...
... A.,Sandler, MD, a West Bloomfield diagnostic radiologist, was installed ... (MSMS) during,the 143rd annual meeting of the MSMS House ... of the Wayne State University School of Medicine, Doctor,Sandler ... at Henry,Ford Hospital and currently serves on the Michigan ...
... HARBIN, China, May 12 /Xinhua-PRNewswire-FirstCall/ -- China ... Yingxia" or "the,Company"), a leading provider in ... and distribution of organic nutritional food,products, supplements, ... Republic,of China ("PRC"), announced today it will ...
... hosts nine physicians from Chongqing Bureau of ... HealthPartners,Institute for Medical Education is hosting the ... to visit Minnesota. During their,three-month stay, the ... learn about health plan and hospital administration ...
... 12 Fairbank Farms, a national,ground beef producer, is ... at its Ashville, N.Y., facility and sold through Price,Chopper, ... Wholesale,distributor., The affected product may contain small pieces ... date of 05/13/08, 05/15/08, or a,"Julian date 124" on ...
... 12 PAREXEL International,Corporation (Nasdaq: PRXL ) announced ... 2008 Growth Stock Conference in Chicago, Illinois. James,Winschel, Senior ... formal presentation on PAREXEL at 10:05 a.m. EDT on ... presentation will be available through the,"Investor Relations Webcasts" section ...
Cached Medicine News:Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3Health News:Michael A. Sandler, MD, Installed as President of Michigan State Medical Society 2Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:First Major Chinese Medical Delegation Visits Minnesota 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2Health News:PAREXEL International to Present at Robert W. Baird's 2008 Growth Stock Conference 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... PC visual acuity system allows you access ... B-VAT II. The system includes 10 different ... testing and animated characters. Random character sequencing ... single letter, single line and multiple line ...
Medicine Products: